Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21331779 | 0.80 | HTR6 (0.39) | ROCK2HTR6NSD2ALDH1A1EGFR | |
| SCHEMBL30354041 | 0.79 | HTR6 (0.36) | ROCK2HTR6NSD2ALDH1A1EGFR | |
| SCHEMBL1048762 | 0.79 | HTR6 (0.36) | ROCK2HTR6NSD2ALDH1A1EGFR | |
| SCHEMBL29549095 | 0.79 | ROCK2 (0.57) | ROCK2 | |
| SCHEMBL3764811 | 0.79 | ROCK2 (0.57) | ROCK2 | |
| SCHEMBL16694213 | 0.77 | ROCK2 (0.55) | ROCK2ALDH1A1 | |
| SCHEMBL2296753 | 0.77 | NPSR1 (0.33) | ROCK2HTR6ALDH1A1LMNAMAPT | |
| SCHEMBL29354371 | 0.77 | HTR6 (0.36) | HTR6NSD2ALDH1A1EGFRLMNA | |
| SCHEMBL29353225 | 0.77 | HTR6 (0.36) | HTR6NSD2ALDH1A1EGFRLMNA | |
| SCHEMBL21788 | 0.77 | HTR6 (0.36) | HTR6NSD2ALDH1A1EGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-6958347-B2 | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists | PFIZER INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1578728-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004054981-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040122038-A1 | NPY-5 antagonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | ROCK2 3162/4885HTR6 988/4885CAMKK2 1195/4885 |
| US-20040122038-A1 | NPY-5 antagonists | NPY5R, NPY1R, NPY2R | ROCK2 1808/4885HTR6 120/4885CAMKK2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.